Innovative Bispecific Nanobody Targeting gp160 and Gag-Pol for HIV Infection Intervention
VHH-P783 is a novel humanized bispecific nanobody designed to target both Envelope surface glycoprotein gp160, precursor (env), and Gag-Pol (Gag-Pol). Currently in the Biological Testing phase, this advanced therapeutic modality leverages nanobody technology to address critical mechanisms involved in HIV Infection. VHH-P783's unique bispecific architecture aims to enhance selectivity and binding affinity for core viral antigens, providing a promising therapeutic avenue for the treatment of HIV infection. The focus on Envelope surface glycoprotein gp160, precursor (env), and Gag-Pol (Gag-Pol) underscores its strategic development for robust antiviral activity within this high-need therapeutic area.
| Candidate | VHH-P783 |
| Target | Envelope surface glycoprotein gp160, precursor (env) Gag-Pol (Gag-Pol) |
| Modality | humanized bispecific VHH |
| Indication | HIV Infection |
Licensing Opportunity
VHH-P783 is available for out-licensing and collaborative partnerships. We welcome inquiries from organizations seeking to advance novel HIV infection therapies and explore strategic co-development opportunities.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P783 |
Modality
VHH-P783 utilizes a bispecific nanobody format, consisting of a single-domain antibody targeting the V2 region of the HIV Env trimer, fused via a flexible 15 amino acid linker to another nanobody directed at the CD4-binding site of the same trimer. As camelid-derived nanobodies, these molecules benefit from compact size, high stability, and exceptional tissue penetration—attributes that are particularly advantageous for tackling HIV infection. This architecture confers improved access to viral epitopes that can be structurally hidden from larger antibodies, as well as potentially enhanced resistance to viral escape mechanisms. In addition, the modular nature of VHH-P783 supports its adaptability and broad application against diverse HIV variants.
Target
gp160 and Gag-Pol are essential HIV-1 proteins critical to viral replication and infection. gp160 serves as the precursor to the envelope glycoproteins involved in the entry of HIV into host cells, while Gag-Pol contains key enzymes required for viral assembly and maturation. Both gp160 and Gag-Pol are predominantly expressed in HIV-infected host cells, especially within CD4+ T lymphocytes. As therapeutic targets, gp160 and Gag-Pol are highly conserved and integral to the viral life cycle, making them validated targets for intervention. Targeting gp160 and Gag-Pol using VHH-P783 enables direct interference with HIV’s ability to infect new cells and propagate. The strategic focus on gp160 and Gag-Pol positions VHH-P783 as a valuable asset in next-generation HIV therapy development.
Mechanism of Action
VHH-P783 operates by binding specifically to defined regions of gp160 and Gag-Pol, thereby impeding critical functions essential for HIV-1 entry into host cells. By targeting the V2 and CD4-binding sites of gp160, VHH-P783 can block attachment and fusion processes, effectively neutralizing viral particles and preventing the establishment of infection. The unique bispecific nanobody design also allows for simultaneous inhibition of distinct viral components, potentially leading to a synergistic antiviral effect. The nanobody platform further allows expansion into formats such as antibody-drug conjugates (ADC) or additional bispecific combinations, providing a versatile basis for future HIV therapeutic strategies and combination regimens.
HIV Infection
HIV infection remains a global health challenge, with millions of individuals affected worldwide and high rates of morbidity and mortality if left untreated. The disease is characterized by progressive immune system failure, primarily targeting CD4+ T cells, and predisposes individuals to opportunistic infections and malignancies. Current standard-of-care includes combination antiretroviral therapy (cART) targeting multiple stages of the viral lifecycle. Although these treatments significantly reduce viral load and improve patient outcomes, they do not eradicate the virus and require lifelong adherence, with issues related to resistance and tolerability persisting. Unmet needs include therapies that can achieve durable remission, reduced dosing frequency, and lower risk of resistance. VHH-P783, with its dual targeting of gp160 and Gag-Pol, offers promising potential to address these gaps by blocking critical steps of viral entry and propagation, representing an innovative advance in the management of HIV infection.